FilingReader Intelligence
Hotgen Biotech subsidiary to undergo capital reduction
February 17, 2025 at 06:00 PM UTC•By FilingReader AI
Beijing Hotgen Biotech (SSE:688068) announced plans for a 20 million RMB capital reduction in its subsidiary, Beijing Regen Biotechnology. The reduction will decrease Regen Biotechnology's registered capital from 50 million RMB to 30 million RMB. Hotgen Biotech will retain its 58% controlling stake in the subsidiary after the reduction.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:688068•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Beijing Hotgen Biotech publishes news
Free account required • Unsubscribe anytime